2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3494 Longitudinal ctDNA-based MRD monitoring is prognostic in peripheral T-cell lymphoma: A real-world multi-institutional analysis

Yumeng Zhang, MD, Darryl Nousome, PhD2, Antony Tin, PhD3, Colin J. Thomas, MD4, Basem William, MD, MRCP(UK), FACP5, Christina Poh, MD6, Yun Kyoung Tiger, MD, PhD7, J. Bryce Ortiz, PhD8, Radhakrishnan Ramchandren, MD9, Minetta C Liu, MD10, Stefan K Barta, MD11
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Natera, Inc., Austin, Texas, United States
3 Natera, Inc., Austin, Texas, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 OhioHealth Blood and Marrow Transplant and Cellular Therapy Program, Columbus, Ohio, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Natera, Inc., Austin, Texas, United States
9 Natera, Inc., Austin, Texas, United States
10 Natera, Inc., Austin, Texas, United States
11 University of Pennsylvania, Philadelphia, Pennsylvania, United States

Introduction: Peripheral T-cell lymphomas (PTCL) are a heterogeneous and aggressive group of non-Hodgkin lymphomas associated with poor outcomes and high rates of relapse following first-line therapy. Current tools for response assessment and post-treatment surveillance rely primarily on imaging, which lacks sensitivity for early molecular relapse detection. Circulating tumor DNA (ctDNA)-based MRD assessment has demonstrated strong prognostic value in B-cell lymphoma, but data in PTCL remain limited. We evaluated the clinical utility of longitudinal  ctDNA-based MRD monitoring across PTCL subtypes in a real-world setting.

Methods: This was a retrospective, real-world analysis of patients with PTCL who underwent commercial ctDNA testing using a personalized, whole-exome based, tumor-informed assay (SignateraTM, Natera, Inc.). Baseline ctDNA was defined as the sample collected prior to any therapy initiation, or if no therapy was initiated, the earliest available timepoint. End of therapy (EOT) ctDNA was defined as any sample collected from 21 days before to 90 days after completion of first-line therapy. On-treatment ctDNA clearance was defined as sustained MRD negativity, requiring the last on-treatment timepoint to be negative or at least two consecutive negative timepoints during therapy, and was compared to transient or no clearance. Events were defined as progressive disease (PD) by imaging, positive biopsy, death, or initiation of a new line of therapy; patients without events were censored at last follow-up. Cox proportional hazards models were used (Firth correction was applied in the on-treatment analysis) and analyses were landmarked at EOT. 

Results: Sixty-six patients were included across the following subtypes: AITL/Nodal TFH-cell lymphoma (n=31, 47%), PTCL-NOS (n=15, 23%), ALK-negative ALCL (n=7, 11%), ALK-positive ALCL (n=5, 8%), extranodal NK/T-cell lymphoma nasal type (n=3, 5%), EATL (n=2, 3%), HSTCL (n=2, 3%), and MEITL (n=1, 2%). Median age was 66 years (range 22 to 84); 56% (37/66) were female. Median follow-up was 10 months (range 1 to 50), with 280 ctDNA timepoints collected (median 4 per patient). Baseline ctDNA was available in 17 patients and 16 of 17 (94.1%) were ctDNA-positive. 

At EOT, 33 patients had ctDNA data available (13 MRD-negative, 20 MRD-positive). MRD-positive patients demonstrated significantly inferior event-free survival (EFS) compared to MRD-negative patients (HR: 15.4, 95%CI: 1.99–118.5, P=0.009) with median EFS of 1.51 months in MRD-positive vs not reached in MRD-negative. 

On-treatment ctDNA clearance was assessed in 29 patients and was also strongly prognostic. Patients with transient or no clearance showed significantly shorter EFS compared to MRD-negative patients (HR: 24.3, 95%CI: 3.15–3125.65, P=0.0001), with wide confidence intervals reflecting the limited sample size. Patients with sustained MRD negativity (n=11) experienced no events, with 12-month EFS of 100%, while patients with transient or no clearance (n=18) had 12 events and a median EFS of 2.69 months, with 12-month EFS of 0.19 (95% CI 0.06–0.62).

During post-first-line treatment surveillance, 25 patients had ctDNA data available. patients who were anytime MRD-positive post EOT assessment (n=15) showed inferior EFS compared to those who remained MRD-negative (n=10; HR: 5.01, 95%CI: 1.07-48.02, p=0.04). The median EFS for patients with anytime MRD positivity was 2.79 months vs not reached for MRD-negative. 

Conclusions: In this real-world cohort, ctDNA-based MRD monitoring demonstrated strong and consistent prognostic value across PTCL subtypes. MRD positivity at EOT and failure to achieve sustained on-treatment ctDNA clearance were highly associated with inferior EFS. Critically, patients who achieved sustained MRD negativity on treatment had 100% EFS at 12 months, suggesting that on-treatment ctDNA clearance may serve as an early indicator of durable remission. These preliminary findings suggest ctDNA-based MRD monitoring may have prognostic utility in PTCL and warrants prospective validation.

Yumeng Zhang, MD: Curio Science - Honoraria; Plexus Communications - Honoraria; Acrotech Biopharma - Consultancy (Includes expert testimony); Citius Oncology - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Arima Genomics - Consultancy (Includes expert testimony); Kyowa Hakko Kirin Pharma, Inc. - Consultancy (Includes expert testimony); AbbVie, Inc. - Consultancy (Includes expert testimony)